Somatoform Disorders: Differential Diagnoses & Workup

References

1. Baruffol E, Thilmany MC. Anxiety, depression, somatization and alcohol abuse. Prevalence rates in a general Belgian community sample. Acta Psychiatr Belg. May-Jun 1993;93(3):136-53. [Medline].

2. Martin A, Rauh E, Fichter M, Rief W. A one-session treatment for patients suffering from medically unexplained symptoms in primary care: a randomized clinical trial. Psychosomatics. Jul-Aug 2007;48(4):294-303. [Medline].

3. Smith GR Jr, Monson RA, Ray DC. Psychiatric consultation in somatization disorder. A randomized controlled study. N Engl J Med. May 29 1986;314(22):1407-13. [Medline].

4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC, American Psychiatric Association. 2000.

5. Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA. Mar 24 2004;291(12):1464-70. [Medline].

6. Baumeister H, Härter M. Prevalence of mental disorders based on general population surveys. Soc Psychiatry Psychiatr Epidemiol. May 21 2007;[Medline].

7. Bleichhardt G, Timmer B, Rief W. Cognitive-behavioural therapy for patients with multiple somatoform symptoms--a randomised controlled trial in tertiary care. J Psychosom Res. Apr 2004;56(4):449-54. [Medline].

8. Chioqueta AP, Stiles TC. Suicide risk in patients with somatization disorder. Crisis. 2004;25(1):3-7. [Medline].

9. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. Jun 2004;184:470-6. [Medline].

10. Dickinson WP, Dickinson LM, deGruy FV. A randomized clinical trial of a care recommendation letter intervention for somatization in primary care. Ann Fam Med. Nov-Dec 2003;1(4):228-35. [Medline].

11. Fink P, Sorensen L, Engberg M. Somatization in primary care. Prevalence, health care utilization, and general practitioner recognition. Psychosomatics. Jul-Aug 1999;40(4):330-8. [Medline].

12. Kroenke K, Spitzer RL, deGruy FV 3rd. A symptom checklist to screen for somatoform disorders in primary care. Psychosomatics. May-Jun 1998;39(3):263-72. [Medline].

13. Morriss RK, Gask L, Ronalds C. Clinical and patient satisfaction outcomes of a new treatment for somatized mental disorder taught to general practitioners. Br J Gen Pract. Apr 1999;49(441):263-7. [Medline].

14. Phillips KA. Body dysmorphic disorder: diagnostic controversies and treatment challenges. Bull Menninger Clin. Winter 2000;64(1):18-35. [Medline].

15. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. Apr 2002;59(4):381-8. [Medline].

16. Smith GR Jr, Rost K, Kashner TM. A trial of the effect of a standardized psychiatric consultation on health outcomes and costs in somatizing patients. Arch Gen Psychiatry. Mar 1995;52(3):238-43. [Medline].

17. Smith RC, Gardiner JC, Lyles JS, et al. Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosom Med. Jan-Feb 2005;67(1):123-9. [Medline].

18. Werring DJ, Weston L, Bullmore ET. Functional magnetic resonance imaging of the cerebral response to visual stimulation in medically unexplained visual loss. Psychol Med. May 2004;34(4):583-9. [Medline].

Further Reading

Keywords

somatization, body dysmorphic disorder, conversion disorder, hypochondriasis, somatization disorder, somatoform disorder NOS, somatoform disorder not otherwise specified, unexplained physical symptoms

Contributor Information and Disclosures

Author

William R Yates, MD, Professor of Research, Department of Psychiatry, University of Oklahoma College of Medicine at Tulsa
William R Yates, MD is a member of the following medical societies: Academy of Psychosomatic Medicine, American Academy of Family Physicians, and American Psychiatric Association
Disclosure: Forest Laboratories Grant/research funds Other

Medical Editor

Mohammed A Memon, MD, Medical Director of Geriatric Psychiatry, Department of Psychiatry, Spartanburg Regional Hospital System
Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories
Eduardo Dunayevich, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; BMS Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Other; Northstar Grant/research funds Other; Novartis  Other

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.